| |
Public Act 099-0429 Public Act 0429 99TH GENERAL ASSEMBLY |
Public Act 099-0429 | HB1660 Enrolled | LRB099 06684 JLK 26758 b |
|
| AN ACT concerning State government.
| Be it enacted by the People of the State of Illinois, | represented in the General Assembly:
| Section 5. The Department of Public Health Powers and | Duties Law of the
Civil Administrative Code of Illinois is | amended by changing Section 2310-675 as follows: | (20 ILCS 2310/2310-675) | (Section scheduled to be repealed on January 1, 2016) | Sec. 2310-675. Hepatitis C Task Force. | (a) The General Assembly finds and declares the following: | (1) Viral hepatitis is a contagious and | life-threatening disease that has a substantial and | increasing effect upon the lifespans and quality of life of | at least 5,000,000 persons living in the United States and | as many as 180,000,000 worldwide. According to the U.S. | Department of Health and Human Services (HHS), the chronic | form of the hepatitis C virus (HCV) and hepatitis B virus | (HBV) account for the vast majority of hepatitis-related | mortalities in the U.S., yet as many as 65% to 75% of | infected Americans remain unaware that they are infected | with the virus, prompting the U.S. Centers for Disease | Control and Prevention (CDC) to label these viruses as the | silent epidemic. HCV and HBV are major public health |
| problems that cause chronic liver diseases, such as | cirrhosis, liver failure, and liver cancer. The 5-year | survival rate for primary liver cancer is less than 5%. | These viruses are also the leading cause of liver | transplantation in the United States. While there is a | vaccine for HBV, no vaccine exists for HCV. However, there | are anti-viral treatments for HCV that can improve the | prognosis or actually clear the virus from the patient's | system. Unfortunately, the vast majority of infected | patients remain unaware that they have the virus since | there are generally no symptoms. Therefore, there is a dire | need to aid the public in identifying certain risk factors | that would warrant testing for these viruses. Millions of | infected patients remain undiagnosed and continue to be at | elevated risks for developing more serious complications. | More needs to be done to educate the public about this | disease and the risk factors that warrant testing. In some | cases, infected patients play an unknowing role in further | spreading this infectious disease. | (2) The existence of HCV was definitively published and | discovered by medical researchers in 1989. Prior to this | date, HCV is believed to have spread unchecked. The | American Association for the Study of Liver Diseases | (AASLD) recommends that primary care physicians screen all | patients for a history of any viral hepatitis risk factor | and test those individuals with at least one identifiable |
| risk factor for the virus. Some of the most common risk | factors have been identified by AASLD, HHS, and the U.S. | Department of Veterans Affairs, as well as other public | health and medical research organizations, and include the | following: | (A) anyone who has received a blood transfusion | prior to 1992; | (B) anyone who is a Vietnam-era veteran; | (C) anyone who has abnormal liver function tests; | (D) anyone infected with the HIV virus; | (E) anyone who has used a needle to inject drugs; | (F) any health care, emergency medical, or public | safety worker who has been stuck by a needle or exposed | to any mucosal fluids of an HCV-infected person; and | (G) any children born to HCV-infected mothers. | A 1994 study determined that Caucasian Americans | statistically accounted for the most number of infected | persons in the United States, while the highest incidence | rates were among African and Hispanic Americans. | (3) In January of 2010, the Institute of Medicine | (IOM), commissioned by the CDC, issued a comprehensive | report entitled Hepatitis and Liver Cancer: A National | Strategy for Prevention and Control of Hepatitis B and C . | The key findings and recommendations from the IOM's report | are (A) there is a lack of knowledge and awareness about | chronic viral hepatitis on the part of health care and |
| social service providers, (B) there is a lack of knowledge | and awareness about chronic viral hepatitis among at-risk | populations, members of the public, and policy makers, and | (C) there is insufficient understanding about the extent | and seriousness of the public health problem, so inadequate | public resources are being allocated to prevention, | control, and surveillance programs. | (4) In this same 2010 IOM report, researchers compared | the prevalence and incidences of HCV, HBV, and HIV and | found that, although there are only 1,100,000 HIV/AIDS | infected persons in the United States and over 4,000,000 | Americans infected with viral hepatitis, the percentage of | those with HIV that are unaware they have HIV is only 21% | as opposed to approximately 70% of those with viral | hepatitis being unaware that they have viral hepatitis. It | appears that public awareness of risk factors associated | with each of these diseases could be a major factor in the | alarming disparity between the percentage of the | population that is infected with one of these blood | viruses, but unaware that they are infected. | (5) In light of the widely varied nature of the risk | factors mentioned in this subsection (a), the previous | findings by the Institute of Medicine, and the clear | evidence of the disproportional public awareness between | HIV and viral hepatitis, it is clearly in the public | interest for this State to establish a task force to gather |
| testimony and develop an action plan to (A) increase public | awareness of the risk factors for these viruses, (B) | improve access to screening for these viruses, and (C) | provide those infected with information about the | prognosis, treatment options, and elevated risk of | developing cirrhosis and liver cancer. There is clear and | increasing evidence that many adults in Illinois and in the | United States have at least one of the risk factors | mentioned in this subsection (a). | (6) The General Assembly also finds that it is in the | public interest to bring communities of Illinois-based | veterans of American military service into familiarity | with the issues created by this disease, because many | veterans, especially Vietnam-era veterans, have at least | one of the previously enumerated risk factors and are | especially prone to being affected by this disease; and | because veterans of American military service should enjoy | in all cases, and do enjoy in most cases, adequate access | to health care services that include medical management and | care for preexisting and long-term medical conditions, | such as infection with the hepatitis virus. | (b) There is established the Hepatitis C Task Force
within | the Department of Public Health. The purpose of the Task Force | shall be to: | (1) develop strategies to identify and address the | unmet needs of persons
with hepatitis C in order to enhance |
| the quality of life of persons with hepatitis C by | maximizing
productivity and independence and addressing | emotional, social, financial, and vocational
challenges of | persons with hepatitis C; | (2) develop strategies to provide persons with | hepatitis C greater access to
various treatments and other | therapeutic options that may be available; and | (3) develop strategies to improve hepatitis C | education and awareness. | (c) The Task Force shall consist of 17 members as follows: | (1) the Director of Public Health, the Director of | Veterans' Affairs, and the Director of Human Services,
or | their designees, who shall serve ex officio; | (2) ten public members who shall be appointed by
the | Director of Public Health from the medical, patient, and | service provider communities, including, but not limited | to, HCV Support, Inc.; and | (3) four members of the General Assembly, appointed
one | each by the President of the Senate, the Minority Leader of | the Senate, the Speaker of the House of Representatives, | and the Minority Leader of the House of Representatives. | Vacancies in the membership of the Task Force shall be | filled in the same
manner provided for in the original | appointments. | (d) The Task Force shall organize within 120 days following | the
appointment of a majority of its members and shall select a |
| chairperson and
vice-chairperson from among the members. The | chairperson shall appoint a
secretary, who need not be a member | of the Task Force. | (e) The public members shall serve without compensation and | shall not be reimbursed for necessary expenses incurred in the
| performance of their duties, unless funds
become available to | the Task Force. | (f) The Task Force shall be entitled to call to its | assistance and avail
itself of the services of the employees of | any State, county, or municipal
department, board, bureau, | commission, or agency as it may require and as may be
available | to it for its purposes. | (g) The Task Force may meet and hold hearings as it deems | appropriate. | (h) The Department of Public Health shall provide staff
| support to the Task Force. | (i) The Task Force shall report its findings and | recommendations to the
Governor and to the General Assembly, | along with any legislative bills that it desires to recommend
| for adoption by the General Assembly, no later than December | 31, 2015. | (j) The Task Force is abolished and this Section is | repealed on January 1, 2017 2016 .
| (Source: P.A. 98-493, eff. 8-16-13; 98-756, eff. 7-16-14.)
|
Effective Date: 1/1/2016
|
|
|